FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016518998> ?p ?o ?g. }

• W2016518998 endingPage "42" @default.
• W2016518998 startingPage "32" @default.
• W2016518998 abstract "Triamcinolone acetonide (TAA) is safe and effective corticosteroid that is marketed as an MDI (metered dose inhaler) (Azmacort) for the treatment of asthma. A novel dry powder inhaler (DPI), the Ultrahaler®, has been developed to deliver Azmacort as another alternative to provide non-CFC formulation for the asthmatic patients. The Ultrahaler® is breath actuated and, unlike MDI, does not require coordination of inhalation with the actuation of the device. However, with the Ultrahaler® device, like any dry powder inhalation device, the challenge was the on-target and uniform delivery of the drug at the site of action (lungs) with different dose strengths. Due to the complexities of oral inhaled formulations and the topical nature of drug delivery to the lung for efficacy, the reformulation requires careful consideration and support throughout their development, using a combination of in vitro and in vivo studies. This paper describes in vitro studies and two clinical pharmacokinetic studies conducted in a sequence that helped to establish optimum doses for the Ultrahaler®. In vitro data were used to guide the initial selection of doses that were then compared in vivo using a pharmacokinetic study with a charcoal block. The in vitro tests included quantifying the target-delivered dose, dose uniformity throughout the life of the device, and the particle size distribution. Particle size distribution was measured using multistage liquid impinger (MSLI) or the Andersen Cascade Impactor (ACI). For in vitro testing, TAA was measured by HPLC methods. Based on the preliminary in vitro data for the respirable fraction, dose strengths with an MDI and the Ultrahaler® for the first study were determined. The in vivo assessment consisted of a four-way crossover study following oral inhalation using both MDI (75 and 225 μg/actuation, reference treatment) and comparable respirable doses in the DPI (130 and 360 μg/actuation) devices in healthy volunteers in the presence (lung deposition) and absence (lung and oropharynx deposition) of the charcoal block. Plasma TAA concentrations were determined using a radioimmunoassay (RIA) method. The in vitro data also showed dose proportionality with DPI formulation, and the doses delivered were within 13% of the target doses. A measure of dose uniformity, the relative standard deviation (%RSD) of dose, was less than 15%. Plasma TAA exposure of DPI formulations was compared with that of MDI formulations. Mean ratios (DPI/MDI) of the AUCinf were close to unity for the lower dose strength. However, for the higher dose strength, plasma exposure was higher with the Ultrahaler® formulation as compared with the MDI formulation (mean AUCinf DPI/MDI ratios: 1.96). These differences seem to be due to less than proportional increases in the MDI formulation. Based on these results and using the higher dose strength of the MDI as the comparator, the new dose strengths of the Ultrahaler® were chosen, ie, 100, 225, and 450 μg/actuation. Plasma TAA concentrations were measured by LC/MS/MS methods. The mean TAA concentrations and AUCinf and Cmax values increased in a dose-proportional manner with an increase in dose for the DPI formulation. The pharmacokinetic parameters showed low variability (10%-33%). Fine particle mass (in vitro testing) and TAA exposure in plasma following DPI administration were compared. Fine particle performance in vitro related well with in vivo pharmacokinetic performance (R2 = AUCinf − 0.9998, Cmax − 0.9956). In conclusion, in vitro and in vivo data were in agreement and good control over the target-dose delivery and dose proportionality could be achieved in the early stages of the development of the Ultrahaler® device and were critical in guiding and ensuring the success of the reformulation efforts for Azmacort." @default.
• W2016518998 created "2016-06-24" @default.
• W2016518998 creator A5000594102 @default.
• W2016518998 creator A5026043428 @default.
• W2016518998 creator A5035083183 @default.
• W2016518998 creator A5044223656 @default.
• W2016518998 date "2006-01-01" @default.
• W2016518998 modified "2023-09-23" @default.
• W2016518998 title "Development of a Dry Powder Inhaler, the Ultrahaler??, Containing Triamcinolone Acetonide Using In Vitro-In Vivo Relationships" @default.
• W2016518998 cites W1524870590 @default.
• W2016518998 cites W1599932614 @default.
• W2016518998 cites W1743507530 @default.
• W2016518998 cites W1987336563 @default.
• W2016518998 cites W1991241124 @default.
• W2016518998 cites W2008742573 @default.
• W2016518998 cites W2015124849 @default.
• W2016518998 cites W2018202338 @default.
• W2016518998 cites W2081441319 @default.
• W2016518998 cites W2085964592 @default.
• W2016518998 cites W2156178115 @default.
• W2016518998 cites W2161865101 @default.
• W2016518998 doi "https://doi.org/10.1097/01.mjt.0000145357.13410.a9" @default.
• W2016518998 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16428920" @default.
• W2016518998 hasPublicationYear "2006" @default.
• W2016518998 type Work @default.
• W2016518998 sameAs 2016518998 @default.
• W2016518998 citedByCount "7" @default.
• W2016518998 countsByYear W20165189982023 @default.
• W2016518998 crossrefType "journal-article" @default.
• W2016518998 hasAuthorship W2016518998A5000594102 @default.
• W2016518998 hasAuthorship W2016518998A5026043428 @default.
• W2016518998 hasAuthorship W2016518998A5035083183 @default.
• W2016518998 hasAuthorship W2016518998A5044223656 @default.
• W2016518998 hasConcept C112705442 @default.
• W2016518998 hasConcept C126322002 @default.
• W2016518998 hasConcept C136229726 @default.
• W2016518998 hasConcept C141071460 @default.
• W2016518998 hasConcept C147789679 @default.
• W2016518998 hasConcept C150903083 @default.
• W2016518998 hasConcept C185592680 @default.
• W2016518998 hasConcept C187530423 @default.
• W2016518998 hasConcept C202751555 @default.
• W2016518998 hasConcept C207001950 @default.
• W2016518998 hasConcept C2776042228 @default.
• W2016518998 hasConcept C2776954882 @default.
• W2016518998 hasConcept C2777419714 @default.
• W2016518998 hasConcept C2778903070 @default.
• W2016518998 hasConcept C2780261241 @default.
• W2016518998 hasConcept C2780350004 @default.
• W2016518998 hasConcept C2780667556 @default.
• W2016518998 hasConcept C42219234 @default.
• W2016518998 hasConcept C55493867 @default.
• W2016518998 hasConcept C71924100 @default.
• W2016518998 hasConcept C86803240 @default.
• W2016518998 hasConcept C98274493 @default.
• W2016518998 hasConceptScore W2016518998C112705442 @default.
• W2016518998 hasConceptScore W2016518998C126322002 @default.
• W2016518998 hasConceptScore W2016518998C136229726 @default.
• W2016518998 hasConceptScore W2016518998C141071460 @default.
• W2016518998 hasConceptScore W2016518998C147789679 @default.
• W2016518998 hasConceptScore W2016518998C150903083 @default.
• W2016518998 hasConceptScore W2016518998C185592680 @default.
• W2016518998 hasConceptScore W2016518998C187530423 @default.
• W2016518998 hasConceptScore W2016518998C202751555 @default.
• W2016518998 hasConceptScore W2016518998C207001950 @default.
• W2016518998 hasConceptScore W2016518998C2776042228 @default.
• W2016518998 hasConceptScore W2016518998C2776954882 @default.
• W2016518998 hasConceptScore W2016518998C2777419714 @default.
• W2016518998 hasConceptScore W2016518998C2778903070 @default.
• W2016518998 hasConceptScore W2016518998C2780261241 @default.
• W2016518998 hasConceptScore W2016518998C2780350004 @default.
• W2016518998 hasConceptScore W2016518998C2780667556 @default.
• W2016518998 hasConceptScore W2016518998C42219234 @default.
• W2016518998 hasConceptScore W2016518998C55493867 @default.
• W2016518998 hasConceptScore W2016518998C71924100 @default.
• W2016518998 hasConceptScore W2016518998C86803240 @default.
• W2016518998 hasConceptScore W2016518998C98274493 @default.
• W2016518998 hasIssue "1" @default.
• W2016518998 hasLocation W20165189981 @default.
• W2016518998 hasLocation W20165189982 @default.
• W2016518998 hasOpenAccess W2016518998 @default.
• W2016518998 hasPrimaryLocation W20165189981 @default.
• W2016518998 hasRelatedWork W161684114 @default.
• W2016518998 hasRelatedWork W1735104919 @default.
• W2016518998 hasRelatedWork W1963533408 @default.
• W2016518998 hasRelatedWork W1986606700 @default.
• W2016518998 hasRelatedWork W2016518998 @default.
• W2016518998 hasRelatedWork W2140730458 @default.
• W2016518998 hasRelatedWork W2405123312 @default.
• W2016518998 hasRelatedWork W2410272602 @default.
• W2016518998 hasRelatedWork W2786895937 @default.
• W2016518998 hasRelatedWork W4249858658 @default.
• W2016518998 hasVolume "13" @default.
• W2016518998 isParatext "false" @default.
• W2016518998 isRetracted "false" @default.
• W2016518998 magId "2016518998" @default.
• W2016518998 workType "article" @default.